Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · regulatory

Hikma advances its epinephrine nasal spray with multi-market regulatory filings

10 September 2026 · By · Wire by Fusion42

Published

10 September 2026

Topic

regulatory

◆ Sectors

MedtechDrug Discovery

◆ Source

Read at prnewswire.com →

◆ Verified

Fusion42 · 10 September 2026 · Fusion42 review

Hikma Pharmaceuticals has submitted regulatory filings for its epinephrine nasal spray across multiple markets, aiming to progress its approval and commercial availability.

This Wire brief sits within Fusion42's coverage of Medtech and Drug Discovery.

◆ ◆ The Wire takeaway

You make drug development decisions now facing faster multi-market regulatory filings for novel formulations like nasal epinephrine. This widens your exit options and forces prioritisation of cross-border regulatory strategies.

◆ Coverage

1 source · 10 Sep 2026

◆ Related on Wire

◆ Topics

MedtechDrug Discoveryepinephrinenasal-spraydrug-regulationmulti-marketpharma